SCHEMBL3301709

SCHEMBL3301709

COC(=O)c1ccc(Nc2nccc(Nc3ccc(F)cc3)n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
NPC1 O15118 4/20 0.69
RAB9A P51151 4/20 0.69
MAPT P10636 3/20 0.69
MAPK1 P28482 3/20 0.69
LMNA P02545 2/20 0.69
ALOX12 P18054 1/20 0.69
AURKA O14965 8/20 0.67
ROCK1 Q13464 1/20 0.64
AURKB Q96GD4 1/20 0.59
MAPK8 P45983 1/20 0.57
ALDH1A1 P00352 1/20 0.57
USP2 O75604 2/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2C19 P33261 2/20 0.54
HTT P42858 1/20 0.52
KDM4E B2RXH2 1/20 0.52
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3303484 0.86 AURKA (0.64) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3304446 0.86 AURKA (0.60) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3300205 0.85 AURKA (0.86) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL13502761 0.81 AURKA (0.62) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL13502762 0.80 AURKA (0.60) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL28645806 0.79 AURKA (0.58) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29360206 0.79 MEN1 (0.73) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5415723 0.79 MEN1 (0.74) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL4467991 0.79 ROCK1 (0.63) MEN1KMT2AAURKAROCK1MAPK8
SCHEMBL12968745 0.79 ROCK1 (1.00) MEN1KMT2AAURKAROCK1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
CN-101605783-A Novel N, N' -2, 4-dianilinopyrimidine derivatives as drugs, pharmaceutical compositions, especially as IKK inhibitors, and preparation thereof SANOFI AVENTIS (FR) 2009-12-16 CN disclosed
EP-2118092-A1 NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS Sanofi-Aventis (FR) 2009-11-18 EP disclosed
WO-2009056693-A1 NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed
WO-2008099073-A1 N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF SANOFI-AVENTIS (FR) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE MEN1 3381/4885KMT2A 2104/4885NPC1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.